PDEs as drug targets for CNS immune disorders.
PDEs are important second messenger systems governing a host of cellular functions involved in neural signal transduction in the CNS and inflammatory cell signaling in the immune system. The contributions of PDE family members as novel treatments that target neuroinflammation as a pathophysiological process in the neuropathogenesis of diverse neurological and psychiatric brain disorders with prominent immune system correlates are discussed.
Hebb
Andrea L O
AL
Dalhousie University, Faculty of Medicine, Department of Pharmacology, Sir Charles Tupper Medical Building, 5850 College Street, Halifax, Nova Scotia, B3H 1X5, Canada.
Robertson
Harold A
HA
D000818:Animals; D020274:Autoimmune Diseases of the Nervous System / Q000188:drug therapy* / Q000276:immunology*; D003865:Major Depressive Disorder / Q000188:drug therapy / Q000523:psychology; D004298:Dopamine / Q000502:physiology; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D018377:Neurotransmitter Agents / Q000502:physiology; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D010727:Phosphoric Diester Hydrolases / Q000502:physiology*; D012559:Schizophrenia / Q000378:metabolism / Q000503:physiopathology; D015398:Signal Transduction / Q000187:drug effects
D004791:Enzyme Inhibitors; D018377:Neurotransmitter Agents; D010726:Phosphodiesterase Inhibitors; D010727:Phosphoric Diester Hydrolases; D004298:Dopamine